Pri-Med News & Industry Features

It’s Great Practice to have People Confident About PrEP Choices

Fri, 05 Dec 2025 16:52:41 +0000

Overview: Understand why HIV prevention is part of a broader health strategy and hear Dr. Yolanda Lawson, MD advocate for the importance of optimizing clinic workflows and training and educating all staff on LA PrEP to ensure a seamless implementation process. This episode highlights the intersection of HIV with other chronic conditions and offers guidance for holistic patient care.

This content is developed exclusively by or on behalf of the industry sponsor through a third party and is not reviewed by Pri-Med. The content and opinions expressed are those of the sponsor or presenters and may not reflect the views of Pri-Med.

For more information, please visit: https://www.pri-med.com/clinical-resources/Curriculum/prep-and-progress

PrEPared to Care: Patient Stories, Sexual Health, and the Power of PrEP (Part #2)

Fri, 05 Dec 2025 16:52:36 +0000

Overview: Explore part #2 with Dr. Nasser Mohammed, Angela Kapalko, and Dr. Robert Morris for a continuation of holistic discussion around case-based HIV prevention strategies to engage patients around the importance of sexual health and self-empowerment. Understand how the PrEP discussion fits into a sexual health conversation. Using another case, discuss how to incorporate the PrEP discussion and management in patient care.

For more information, please visit: https://www.pri-med.com/clinical-resources/Curriculum/prep-and-progress

PrEPared to Care: Patient Stories, Sexual Health, and the Power of PrEP (Part #1)

Fri, 05 Dec 2025 16:52:30 +0000

Overview: Join Dr. Nasser Mohammed, Angela Kapalko, and Dr. Robert Morris for a holistic discussion around case-based HIV prevention strategies to engage patients around the importance of sexual health and self-empowerment. Understand how the PrEP discussion fits into a sexual health conversation. Using a case-based approach, discuss how to incorporate the PrEP discussion and management in patient care.

Missed Opportunities in HIV Prevention

Tue, 11 Nov 2025 15:59:43 +0000

Overview: In this episode, Toyin Nwafor, MD, and Christian B Ramers, MD, draw on their experience in primary care, HIV and HIV prevention to highlight missed opportunities for HIV prevention and discuss strategies to help address gaps in the HIV care continuum.

The views expressed are those of the panelist(s) and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2025 and the content reflects the information available at that time.

Guest: Toyin Nwafor, MD; Christian B Ramers, MD, MPH, FIDSA, AAHIVS

For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus

References

AIDSVu.org. Prevalence in the United States. 2022. Available from: https://map.aidsvu.org/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51.

CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025).

CDC. Discussing sexual health with your patients. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/sexual-history/index.html (Accessed June 25, 2025).

CDC.gov. HIV diagnoses, deaths, and prevalence. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html (Accessed June 25, 2025).

CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025).

CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2021 update: a clinical practice guideline. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025).

Doblecki-Lewis S et al. J Int Assoc Provid AIDS Care 2019;18:2325958219848848.

DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025).

HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025).

HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025).

HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed May 21, 2025).

HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed July 18, 2025).

HIV.gov. Who is at risk for HIV. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/about-hiv-and-aids/who-is-at-risk-for-hiv (Accessed June 25, 2025).

Johns Hopkins Bloomberg School of Public Health. What to know about PrEP. 2025. Available from: https://publichealth.jhu.edu/2025/who-needs-prep-for-hiv-prevention (Accessed June 25, 2025).

Kamis KF et al. Open Forum Infect Dis 2019;6:ofz310.

KFF. HIV testing in the United States. 2024. Available from: https://www.kff.org/hiv-aids/hiv-testing-in-the-united-states/ting in the United States | KFF (Accessed August 26, 2025).

NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-infections-stis (Accessed June 25, 2025).

Ramchandani MS et al. Curr HIV/AIDS Rep 2019;16:244–56.

Saag MS et al. JAMA 2018;320:379–96.

Sweeney P et al. J Acquir Immune Defic Syndr 2019;82(Suppl 1):S1–5.

The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025).

UNAIDS.org. Recommended 2030 targets for HIV. 2025. Available from: https://www.unaids.org/en/recommended-2030-targets-for-hiv (Accessed August 26, 2025).

United States Census Bureau. National population by characteristics: 2020-2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025).

United States Census Bureau. United States Population Growth by Region. 2025. Available from: https://www.census.gov/popclock/ (Accessed June 25, 2025).

Yumori C et al. Sex Transm Dis 2021;48:32–6.

PrEP Landscape Overview

Tue, 11 Nov 2025 15:59:33 +0000

Overview: In this episode, Dr Gina Brown and Dr Sahar Khalili draw on their expertise in HIV prevention to provide an overview of the current PrEP landscape in the United States. They highlight advancements in HIV prevention and emphasize the importance of targeted programs to address disparities in access and uptake across population groups and geographic regions.

Guest: Gina Brown, MD; Sahar Khalili, PharmD

For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus

References

ACOG. Preexposure prophylaxis for the prevention of human immunodeficiency virus. 2024. Available from: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2022/06/preexposure-prophylaxis-for-the-prevention-of-human-immunodeficiency-virus (Accessed June 25, 2025).

ADAP Directory. About. 2024. Available from: https://adap.directory/about (Accessed June 25, 2025).

Aidsmap. Condoms. 2023. Available from: https://www.aidsmap.com/about-hiv/condoms#toc-how-effective-are-condoms (Accessed June 25, 2025).

AIDSVu. AIDSVu releases new PrEP data and launches PrEPVu.org, a new PrEP equity platform. 2024. Available from: https://aidsvu.org/news-updates/aidsvu-releases-new-prep-data-and-launches-prepvu-org-a-new-prep-equity-platform/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

AIDSVu. AIDSVu releases 2024 PrEP use data showing growing use across the U.S. 2025. Available from: https://aidsvu.org/news-updates/aidsvu-releases-2024-prep-use-data-showing-growing-use-across-the-u-s/ (Accessed July 18, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

AIDSVu. Location profiles: South. 2025. Available from: https://map.aidsvu.org/profiles/region/south/prevention-and-testing#1-2-PnR (Accessed July 31, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

AIDSVu. PrEP use significantly associated with decreasing new HIV diagnoses across U.S. states. 2025. Available from: https://aidsvu.org/news-updates/prep-use-significantly-associated-with-decreasing-new-hiv-diagnoses-across-u-s-states/ (Accessed June 25, 2025). AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

Baeten J et al. Curr HIV/AIDS Rep 2013;10:142–51.

Bekker LG et al. N Engl J Med 2024;391:1179–92.

CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 2, 2025).

CDC. Clinical Guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 25, 2025).

CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 update. 2021. Available from: https://stacks.cdc.gov/view/cdc/112360 (Accessed June 25, 2025).

Coates TJ et al. Lancet 2008;372:669–84.

DHHS. Pre-exposure (PrEP) to prevent HIV during periconception, antepartum, ad postpartum. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/perinatal-hiv/pre-exposure-prophylaxis-prep-prevent-hiv-perinatal.pdf (Accessed June 25, 2025).

Gandhi RT et al. JAMA 2023;329:63–84.

HIV.gov. HIV treatment as prevention. 2023. Available from: https://www.hiv.gov/tasp (Accessed June 25, 2025).

HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 2, 2025).

HIV.gov. Pre-exposure prophylaxis. 2025. Available from: https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis (Accessed June 25, 2025).

Kelley CF et al. N Engl J Med 2025;392:1261–76.

Kourtis AP et al. Ann Epidemiol 2025:106:48-54.

Landers S et al. Am J Public Health 2017;107:1534–35.

Landovitz RJ et al. N Engl J Med 2021;385:595–608.

NIH. HIV and sexually transmitted infections (STIs). 2021. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-sexually-transmitted-diseases-stds (Accessed June 25, 2025).

NIH. HIV medicines during pregnancy and childbirth. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-medicines-during-pregnancy-and-childbirth (Accessed July 31, 2025)

NIH. Post-exposure prophylaxis (PEP). 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/post-exposure-prophylaxis-pep (Accessed June 25, 2025).

NIH. PrEP to prevent HIV and promote sexual health. 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556471/ (Accessed June 25 2025).

Siegler AJ et al. Ann Epidemiol 2020;45:24–31.e37

Sullivan PS et al. J Int AIDS Soc 2025;28:e26459.

Townes A et al. Obstet Gynecol 2023;143:294–301.

Underhill K et al. PLoS Med 2007;4:e275.

United States Census Bureau. National population by characteristics: 2020–2024. 2024. Available from: https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html (Accessed June 25, 2025).

Owens DK et al. JAMA 2019;321:2326–36.

Vermund SH et al. J Acquir Immune Defic Syndr 2013;63:S12–25.

Washington State Department of Health. Pre-exposure prophylaxis drug assistance program (PrEP DAP). Available from: https://doh.wa.gov/you-and-your-family/illness-and-disease-z/hiv/prevention/pre-exposure-prophylaxis-drug-assistance-program-prep-dap (Accessed June 25, 2025).

World Health Organization. Global HIV programme: pre-exposure prophylaxis (PrEP). Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/prevention/pre-exposure-prophylaxis (Accessed June 25, 2025).

Rapid Start, Restart for HIV Treatment

Tue, 11 Nov 2025 15:59:21 +0000

Overview: In this episode, Dr Toyin Nwafor and Dr Andrew Zolopa provide an overview of the HIV treatment landscape both globally and in the United States. They highlight the current gaps in the HIV care continuum, emphasize the importance of rapid start and viral suppression in reducing HIV transmission through sex and describe initiatives and strategies aimed at closing these gaps to help end the HIV epidemic in the United States.

Guest: Toyin Nwafor, MD; Andrew Zolopa, MD

For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus

References

AETC. Rapid (immediate) ART initiation and restart: guide for clinicians. 2023. Available from: https://aidsetc.org/resource/rapid-immediate-art-initiation-restart-guide-clinicians (Accessed June 25, 2025).

Baxter A et al. J Acquir Immune Defic Syndr 2025;99:47–54.

CDC. About ending the HIV epidemic in the US. 2024. Available from: https://www.cdc.gov/ehe/php/about/index.html (Accessed June 25, 2025).

CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 25, 2025).

CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/index.html#cdc_testing_why_get_tested-why-get-tested (Accessed June 25, 2025).

CDC. Laboratory testing for the diagnosis of HIV infection. 2014. Available from: https://stacks.cdc.gov/view/cdc/23446 (Accessed June 25, 2025).

CDC. National HIV prevention and care objectives: 2025 update. 2025. Available from: https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2025.html (Accessed June 25, 2025).

Delaney KP et al. Am J Prev Med 2021;61(5 Suppl 1):S6–S15.

DHHS. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf (Accessed June 25, 2025).

HIV.gov. EHE overview. 2025. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview (Accessed June 25, 2025).

HIV.gov. Global statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics (Accessed June 25, 2025).

HIV.gov. HIV Care Continuum. 2025. Available from: https://www.hiv.gov/federal-response/other-topics/hiv-aids-care-continuum (Accessed June 25, 2025).

HIV.gov. Key EHE strategies. 2024. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/key-strategies (Accessed June 25, 2025).

HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 25, 2025).

HIV.gov. Viral suppression and undetectable viral load. 2025. Available from: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/hiv-treatment/viral-suppression (Accessed June 25, 2025).

Mirzazadeh A et al. PLoS Med 2022;19:e1003940.

NIH. HIV testing. 2025. Available from: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-testing (Accessed June 25, 2025).

Palacio-Vieira J et al. BMC Public Health 2021;21:1596.

Saag MS et al. JAMA 2018;320:379–96.

The White House. National HIV/AIDS strategy for the United States 2022–2025. 2021. Available from: https://files.hiv.gov/s3fs-public/NHAS-2022-2025.pdf (Accessed June 25, 2025).

WHO. Supporting re-engagement in HIV treatment services: policy brief. 2024. Available from: https://www.who.int/publications/i/item/9789240097339 (Accessed June 25, 2025).

The Importance of Pan-viral Screening

Tue, 11 Nov 2025 15:59:02 +0000

Overview: In this episode, Dr Melissa Jones and Dr Christian Ramers discuss the importance of pan-viral screening for HIV and hepatitis. They emphasize the need for integrated testing and prevention strategies and the current barriers to implementation.

Guest: Christian B Ramers, MD, MPH, FIDSA, AAHIVS; Melissa Jones, DNP, APRN-BC

For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus

References

AASLD/IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. 2025. Available from: https://www.hcvguidelines.org/ (Accessed June 10, 2025).

Arora DR et al. ISRN AIDS 2013;2013:287269

Alter MJ. J Hepatol 2006;44:S6–9.

Bazargan M, Cobb BMS, Assari S. Ann Fam Med 2021;19:4–15.

Beard N, Hill A. Open Forum Infect Dis 2024;11:ofad666.

Bottero J, Boyd A, Gozlan J et al. Open Forum Infect Dis 2015;2:ofv162.

Brunetto, Maurizia Rossana et al. J Hepatol 2023;79:433–60.

Calabrese SK, Krakower DS, Mayer KH. Am J Public Health 2017;107:1883–89.

CDC. Status neutral HIV care and service delivery eliminating stigma and reducing health disparities. 2022. Available from: https://stacks.cdc.gov/view/cdc/129024 (Accessed June 10, 2025).

CDC. Clinical guidance for PrEP. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/prep/index.html (Accessed June 10, 2025).

CDC. Clinical screening and diagnosis for hepatitis C. 2025. Available from: https://www.cdc.gov/hepatitis-c/hcp/diagnosis-testing (Accessed June 10, 2025).

CDC. Clinical testing and diagnosis for hepatitis B. 2025. Available from: https://www.cdc.gov/hepatitis-b/hcp/diagnosis-testing/ (Accessed June 10, 2025).

CDC. Clinical testing guidance for HIV. 2025. Available from: https://www.cdc.gov/hivnexus/hcp/diagnosis-testing/index.html (Accessed June 10, 2025).

CDC. Getting tested for HIV. 2025. Available from: https://www.cdc.gov/hiv/testing/ (Accessed June 10, 2025).

CDC. Hepatitis A vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-a/vaccination/index.html (Accessed June 10, 2025).

CDC. Hepatitis B vaccine. 2025. Available from: https://www.cdc.gov/hepatitis-b/vaccination/index.html (Accessed June 10, 2025).

CDC. HIV infection among heterosexuals at increased risk--United States, 2010. MMWR Morb Mortal Wkly Rep 2013;62:183-8.

CDC. Viral hepatitis among people with HIV. 2025. Available from: https://www.cdc.gov/hepatitis/hcp/populations-settings/hiv.html (Accessed June 10, 2025.

Clinical info HIV.gov. Considerations for Antiretroviral Use in People With Coinfections, Hepatitis B Virus/HIV Coinfection. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/hepatitis-b-virus-hiv-coinfection (Accessed July 21, 2025).

Cornberg M, Sandmann L, Jaroszewicz J et al. J Hepatol 2025; doi: 10.1016/j.jhep.2025.03.018.

Coukan F, Murray KK, Papageorgiou V et al. HIV Med 2023;24:893–913.

GHTF. Breaking the silence: combating stigma and misinformation in the fight against hepatitis. 2024. Available from: https://www.globalhep.org/news-blogs/breaking-silence-combating-stigma-and-misinformation-fight-against-hepatitis (Accessed June 10, 2025)

Grieb SM, Harris R, Rosecrans A et al. Ann Med 2022;54:138–49.

HIV.gov. US statistics. 2025. Available from: https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics (Accessed June 10, 2025).

Kitt H et al. HIV testing, PrEP, new HIV diagnoses and care outcomes for people accessing HIV services: 2024 report. 2024. Available from https://www.gov.uk/government/statistics/hiv-annual-data-tables/hiv-testing-prep-new-hiv-diagnoses-and-care-outcomes-for-people-accessing-hiv-services-2024-report (Accessed June 10, 2025)

Mayer KH, Agwu A, Malebranche D. Adv Ther 2020;37:1778–811.

Mohareb AM, Larmarange J, Kim AY et al. Lancet HIV 2022;9:e585–e94.

Moorman AC, Bixler D, Teshale EH et al. Public Health Rep 2023; doi: 10.1177/00333549231181348

Orkin, C. Open Forum Infect Dis 2024;11:ofad668.

Post Z et al. Clin Liver Dis 2023;27:973-84

Saleska JL, Lee SJ. JAMA Pediatr 2020;174:1133–34.

Symum H, Van Handel M, Sandul A et al. Prev Med Rep 2024;44:102777.

UNAIDS. Global HIV & AIDS statistics — Fact sheet. 2025. Available from: https://www.unaids.org/en/resources/fact-sheet (Accessed July 18, 2025).

UNM. Project ECHO. 2025. Available from: https://projectecho.unm.edu/ (Accessed June 10, 2025).

Wejnert C et al. MMWR Morb Mortal Wkly Rep. 2016;65:1336–1342

WHO. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations (Geneva). 2022. Available from: https://www.who.int/publications/i/item/9789240052390 (Accessed June 10, 2025).

WHO. Fact sheet: hepatitis A. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a (Accessed June 10, 2025).

WHO. Fact sheet: hepatitis B. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b (Accessed July 18, 2025).

WHO. Fact sheet: hepatitis D. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-d (Accessed June 10, 2025).

WHO. Guidelines on HIV self-testing and partner notification: a supplement to the consolidated guidelines on HIV testing services. 2016. Available from: https://iris.who.int/handle/10665/251655 (Accessed June 10, 2025).

WHO. Recommendations and guidance on hepatitis C virus self-testing. 2021. Available from: https://www.who.int/publications/i/item/9789240031128 (Accessed June 10, 2025).

Xiao Y et al. Cells. 2020;9:2233

History of the AIDS Epidemic Including HIV Drug Resistance

Tue, 11 Nov 2025 15:55:33 +0000

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time.

Guest: Joel Gallant, MD, MPH

For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus

References

AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc.

Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5

Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001

Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183

Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002

Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm

Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025)

Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243

Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251

Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025)

Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X

Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502

Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281

Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025)

Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025)

Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152

Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102

Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47

HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025)

HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025)

HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025)

i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025)

Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095

Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026

Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016

Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383

Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5

Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X

Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2

Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/

Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8

Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023

National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025)

Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33

New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025)

Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020

Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025)

Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402

Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010

Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880

Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975

TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025)

U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

How Blood Tests are Revolutionizing Alzheimer’s Diagnosis

Wed, 15 Jan 2025 19:02:24 +0000

Overview: Explore the evolving landscape of Alzheimer’s diagnosis, where blood tests are emerging as a critical tool in clinical practice. In this episode, we’ll examine how these tests add value to traditional diagnostic methods and the latest research validating their accuracy. Join us to discover the potential of blood tests in transforming Alzheimer’s diagnosis.

Guest: Suzanne E. Schindler, MD, PhD, Associate Professor of Neurology, Washington University School of Medicine

For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-1

From Lab to Practice: Integrating Alzheimer’s Blood Tests into Primary Practice

Wed, 15 Jan 2025 19:02:19 +0000

Overview: With the foundational knowledge from Episode 1, we transition from theory to practice. As these diagnostic tools become more widespread, primary care clinicians are at the forefront of their implementation. Listeners will gain insights from real-world experiences, learning actionable strategies to overcome challenges such as logistical barriers and resource limitations. By the end of this episode, primary care clinicians will have a roadmap for implementing blood tests into their practice.

Guest: Deanna Willis, MD, MBA, FAAFP, FNAP; Jared Brosch, MD

For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-2

Navigating Ethics and Communication: Delivering Alzheimer’s Blood Test Results

Wed, 15 Jan 2025 19:02:13 +0000

Overview: As blood tests for Alzheimer’s become more accessible, clinicians must navigate the ethical and emotional complexities of delivering life-changing results. We explore how to communicate these findings with care, manage the psychological impact on patients and families, and address uncertainty in ambiguous cases. Drawing on real-world experiences and research, discover practical guidance for balancing clinical responsibility with compassionate patient care.

Guest: Michelle M. Mielke, PhD; Allyson Rosen, PhD, ABPP-CN

For more information, please visit: https://www.pri-med.com/clinical-resources/podcast/ceoi-alzheimers-diagnostics-pt-3

Are eosinophils a good biomarker in severe asthma?

Thu, 02 Nov 2023 15:31:25 +0000

Overview: In this episode, join us as we discuss the use of blood eosinophils as a biomarker in severe asthma and whether there is prognostic value in measuring eosinophil levels.

Episode key references and resource links:

Bruselle GG, and Koppelman GH. N Engl J Med. 2022;386(2):157–171.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
de Groot JC, et al. ERJ Open Research. 2015;1(1):00024–2015.
Bousquet J, et al. N Engl J Med. 1990;323(15):1033–1039.
Yancey SW, et al. J. Allergy Clin Immunol. 2017;140(6):1509–1518.

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

When should you refer to a specialist?

Thu, 02 Nov 2023 15:31:17 +0000

Overview: In this episode, join us as we discuss the risks of elevated eosinophil levels and exacerbations, and the role a specialist can play in the management of severe asthma.

Episode references and resource links:

Price DB, et al. Lancet Respir Med. 2015;3(11):849–858.
Dougherty RH and Fahy JV. Clin Exp Allergy. 2008;39(2):193–202.
Chung LP, et al. Respirology. 2020;25(2):161–172.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
Agusti A, et al. Respir Med. 2021;187:106572.

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

Should you measure blood eosinophil levels in patients with severe asthma?

Thu, 02 Nov 2023 15:30:38 +0000

Overview: In this episode, join us as we discuss the importance of blood eosinophil testing for improving diagnosis and phenotyping in severe asthma.

Episode key references and resource links:

Bruselle GG, and Koppelman GH. N Engl J Med. 2022;386(2):157–171.
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023. Available from: https://ginasthma.org/2023-gina-main-report/. Access date [June 2023].
Heaney LG, et al. Chest. 2021;160(3):814–830.
de Groot JC, et al. ERJ Open Research. 2015;1(1):00024–2015.
Fitzpatrick AM, et al. J Allergy Clin Immunol Pract. 2020;8(2):452–463

Guest: Dareen Siri, MD, FAAAAI, FACAAI and Matthew Mintz, MD, FACP

The Pathophysiology of Older Adults with Type 2 Diabetes

Tue, 16 May 2023 13:25:47 +0000

This podcast will review the unique pathophysiology in older adults with long-term Type 2 diabetes that underlie requirements for combination insulin therapy.

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

Framework for Approaching the Treatment of Older Adults with Type 2 Diabetes

Tue, 16 May 2023 13:25:37 +0000

This podcast reviews the specific considerations in appropriately individualizing care for older adults with T2D by reviewing health status, cognition, frailty and their living situation

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

Treatment Selection for Older Adults with Type 2 Diabetes

Tue, 16 May 2023 13:25:22 +0000

This podcast focuses on the exploration of treatment approaches in older patients with Type 2 diabetes who are insulin-requiring through case discussion with a focus on simplicity, minimization of hypoglycemia and importance of simplification/de-intensification utilizing an individualized approach by reviewing
psychological, medical, functional and social domains.

Please take a few minutes to answer this questionnaire to help us evaluate the impact of this program and plan for future educational programs. Click Here

Managing Recurrent UTIs: From Prevention to Treatment

Fri, 17 Mar 2023 13:42:42 +0000

The complexity behind recurrent UTI management often leaves both patients and clinicians with questions on the optimal management strategy. Should they be treated as an uncomplicated UTI? Are there special considerations or prevention measures? Are there unforeseen or unknown factors contributing to disease incidence? In this second episode, we take a deep dive into the treatment and management of recurrent UTI and explore the impact that this disease has on patients.

Disclaimers:

This presentation is sponsored by GSK. The speakers are GSK paid healthcare providers. The content is intended to support disease state education and is considered nonpromotional.
The content and views expressed therein do not necessarily reflect the views, policies, or position of Pri-Med. This program is limited to Health Care Professionals (HCPs) only. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs.

References:

Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi: 10.1097/JU.00000000000002963. 
Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227-241. doi: 10.1016/s0891-5520(03)00005-9
Foxman B, Gillespie B, Koopman J, et al. Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000; 151:1194.
Ikäheimo R, Siitonen A, Heiskanen T, et al. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996; 22:91.
Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52:e103.
Markowitz MA, Wood LN, Raz S, Miller LG, Haake DA, Kim JH. Lack of uniformity among United States recommendations for diagnosis and management of acute, uncomplicated cystitis. Int Urogynecol J. 2019;30(7):1187-1194. doi:10.1007/s00192-018-3750-z.
Labcorp Report – Antibiotic Resistance in Bladder Infections (2019). https://www.labcorp.com/organizations/data/insights[1]analysis#InsightAnalytics-Antibiotic. Accessed December 1, 2022.
Langford BJ, Brown KA, Diong C, et al. The Benefits and Harms of Antibiotic Prophylaxis for Urinary Tract Infection in Older Adults. Clin Infect Dis. 2021;73(3):e782-e791. doi:10.1093/cid/ciab116
Harding C, Mossop H, Homer T, et al. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ. 2022;376:e068229. Published 2022 Mar 9. doi:10.1136/bmj-2021-0068229

Patient-Centered Approach to Treating UTIs: Seeking Consensus Through Controversies

Fri, 17 Mar 2023 13:42:34 +0000

Uncomplicated UTIs (Urinary Tract Infections) can have a detrimental impact on emotional wellbeing. Patients may feel ignored by their clinicians, who face a diverse set of challenges when managing uncomplicated UTIs, all of which are important to address when keeping the plan patient-centered. In this podcast, we will discuss patient-clinician communication barriers and the importance of patient[1]centered outcomes in managing uncomplicated UTIs.

Disclaimers:

This presentation is sponsored by GSK. The speakers are GSK paid healthcare providers. The content is intended to support disease state education and is considered nonpromotional.
The content and views expressed therein do not necessarily reflect the views, policies, or position of Pri-Med. This program is limited to Health Care Professionals (HCPs) only. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs.

References:

Hilt EE, McKinley K, Pearce MM, et al. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol. 2014;52(3):871-876. doi:10.1128/JCM.02876-13
Lindsay LE, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis 68, no. 10 (May 2, 2019): e83–110. https://doi.org/10.1093/cid/ciy1121
Advani SD, Polage CR, Fakih MG. Deconstructing the urinalysis: A novel approach to diagnostic and antimicrobial stewardship. Antimicrob Steward Healthc Epidemiol. 2021;1(1):e6. doi: 10.1017/ash.2021.167. Epub 2021 Jun 28. PMID: 34604864; PMCID: PMC8486290
FDA Drug Safety Communication. FDA. 2016. Accessed October 10, 2022 https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety[1]communication-fda-advises-restricting-fluoroquinolone-antibiotic-use-certain
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi: 10.1097/JU.00000000000002963
Thompson J, Marijam A, Mitrani-Gold FS, Wright J, Joshi AV. Activity impairment and health-related emotional wellbeing associated with an uncomplicated urinary tract infection among US females. Oral presentation at: IDWeek 2021; September 29-October 3, 2021; Virtual Conference. Session: UTIs; presentation 196

7.Colgan R, Keating K, Dougouih M. Survey of symptom burden in women with uncomplicated urinary tract infections. Clin Drug Investig. 2004;24(1):55-60. doi: 10.2165/00044011-200424010-00007

Thompson J, Marijam A, Mitrani-Gold FS, Wright J, Joshi AV. A survey study of healthcare resource use, and direct and indirect costs, among females with an uncomplicated urinary tract infection in the United States. Poster presented at: IDWeek 2021; September 29-October 3, 2021. Poster 1227
Grigoryan L, Mulgirigama A, Powell M, Schmiemann G. The emotional impact of urinary tract infections in women: a qualitative analysis. BMC Womens Health. 2022;22(1):182. doi: 10.1186/s12905-022-01757-3
Scott VC, Thum LW, Sadun T, et al. Fear and frustration among women with recurrent urinary tract infections: findings from patient focus groups. J Urol. 2021;206(3):688-695. doi: 10.1097/JU.0000000000001843
Lecky DM, Howdle J, Butler CC, McNulty CA. Optimising management of UTIs in primary care: a qualitative study of patient and GP perspectives to inform the development of an evidence-based, shared decision-making resource. Br J Gen Pract. 2020;70(694):e330-e338. doi: 10.3399/bjgp20X708173
Chwa A, Kavanagh K, Linnebur SA, Fixen DR. Evaluation of methenamine for urinary tract infection prevention in older adults: a review of the evidence. Ther Adv Drug Saf. 2019;10:2042098619876749. Published 2019 Sep 23. doi:10.1177/2042098619876749
Harding C, Mossop H, Homer T, etal. Alternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial. BMJ 2022;376:e068229. doi: 10.1136/bmj-2021-0068229
Wade C, et al. Methenamine Prophylaxis for Recurrent Urinary Tract Infections in a Tertiary Referral Center. Urol Pract 2021;8(8):699-704
Hoffmann TC. Methenamine hippurate for recurrent urinary tract infections. BMJ 2022; 376
De Paepe H, Hoebeke P, Renson C, et al. Pelvic-floor therapy in girls with recurrent urinary tract infections and dysfunctional voiding. Br J Urol. 1998;81 Suppl 3:109-113. doi:10.1046/j.1464-410x.1998.00021.x
Hooton TM, Vecchio M, Iroz A et al. Effect of increased daily water intake in premenopausal women with recurrent urinary tract infections. JAMA Intern Med 2018; 178: 1509
Gupta K, Hooton TM, Naber KG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi: 10.1093/cid/ciq257

Is an Uncomplicated UTI Really Uncomplicated?

Fri, 17 Mar 2023 13:42:24 +0000

The controversy surrounding whether to collect urine cultures and which empiric treatment to prescribe in patients with uncomplicated UTI has left many clinicians unsure of the right approach. In this the first episode of a podcast series, we’ll discuss the definition of clinical cure and dive into the evidence behind grey areas in the diagnosis and management of uncomplicated UTI.

Disclaimers:

This presentation is sponsored by GSK. The speakers are GSK paid healthcare providers. The content is intended to support disease state education and is considered nonpromotional.
The content and views expressed therein do not necessarily reflect the views, policies, or position of Pri-Med. This program is limited to Health Care Professionals (HCPs) only. GSK complies with all state and federal laws including transparent reporting and disclosure of payments and transfers of value to HCPs.

References:

Gupta K, Hooton TM, Naber KG, et al.; Infectious Diseases Society of America; European Society for Microbiology and Infectious Diseases. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103- e120. doi: 10.1093/cid/ciq2572.
Anger J, Lee U, Ackerman AL, et al. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU guideline. J Urol. 2019;202(2):282-289. doi: 10.1097/JU.00000000000002963
Houlbar M, Meng L. SHC Clinical Pathway: Inpatient Management of Urinary Tract Infections – Adult Patients. Stanford Antimicrobial Safety and Sustainability Program. November 2017. https://med.stanford.edu/content/dam/sm/bugsanddrugs/documents/c linicalpathways/SHC-UTI-Inpatient-Guideline.pdf. Accessed November 30, 2022.
Hooton TM, Gupta K. Acute simple cystitis in women. UpToDate. Updated March 15, 2021. Accessed November 9, 2022. https://www.uptodate.com/contents/acute-simple-cystitis-in-women
Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011;84(7):771-776.
Shafrin J, Marijam A, Joshi AV, et al. Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: an analysis of integrated delivery network electronic health records. Antimicrob Resist Infect Control. 2022;11(1):133. Published 2022 Nov 4. doi:10.1186/s13756-022-01170-3
Daneman N, Chateau D, Dahl M, et al. Fluoroquinolone use for uncomplicated urinary tract infections in women: a retrospective cohort study. Clin Microbiol Infect. 2020;26(5):613-618. doi:10.1016/j.cmi.2019.10.016
Bratsman A, Mathias K, Laubscher R, Grigoryan L, Rose S. Outpatient fluoroquinolone prescribing patterns before and after US FDA boxed warning. Pharmacoepidemiol Drug Saf. 2020;29(6):701-707. doi:10.1002/pds.5018
FDA Drug Safety Communication. FDA. 2019. Accessed October 10, 2022 https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns[1]about-increased-risk-ruptures-or-tears-aorta-blood-vessel[1]fluoroquinolone-antibiotics
Nicolle LE; AMMI Canada Guidelines Committee*. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16(6):349- 360. doi:10.1155/2005/385768

Meet The Patient: Decoding IBS-D in Your Practice

Tue, 28 Feb 2023 17:37:08 +0000

Diagnosing and treating IBS-D can be challenging. On IBS-D(ecoded), host Susan Brazil gets the latest facts about IBS-D, and real life patients share their experiences living with IBS-D. In Episode 1, patient Molly from Atlanta discusses her symptoms and frustrations since being first diagnosed with IBS-D ten years ago. Expert physician Dr. Gregory Sayuk introduces treatment options..

US-VBZ-220064 09/22

Meet The Experts: Using the Symptoms to Decode IBS-D

Tue, 28 Feb 2023 17:36:58 +0000

IBS-D was once a diagnosis of exclusion. If a patient didn’t test positive for other gastrointestinal conditions, IBS-D was considered possible. On this episode of IBS-D(ecoded), experts who have been involved in both the research and treatment of IBS-D discuss the symptoms that may help health care providers make an efficient, reliable diagnosis.

US-VBZ-220064 09/22

Meet Nico & Christine: Their IBS-D Journeys Decoded

Tue, 28 Feb 2023 17:36:42 +0000

IBS-D can affect people of all ages, from all walks of life. On this third and final episode of IBS-D(ecoded), we meet two more patients. Nico is a young man who was first diagnosed with IBS-D while in college. Christine is in her 60s and has lived with abdominal pain and diarrhea for decades. Our expert gastroenterologists discuss these patients’ symptoms and treatment options. Then patient Molly, whom we met in Episode 1, returns with some important advice for both health care providers and patients.

US-VBZ-220064 09/22

Episode 5: Sex Differences

Thu, 18 Aug 2022 13:41:28 +0000

Join Dr Hillary Norton and Amanda Mixon, PA as they discuss the sex differences in the presentation of axSpA

Dr Norton is a board-certified rheumatologist based in Santa Fe

Amanda Mixon earned her PA certification at Michigan State University

This podcast is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

This podcast is part of the Think Back: Insights Into Axial Spondyloarthritis curriculum.

Episode 4: IBP vs MBP

Thu, 18 Aug 2022 13:41:21 +0000

Join Dr Robert Sallis and Dr Steve Lee as they discuss the differentiation of inflammatory back pain and mechanical back pain in axSpA

Dr Sallis is a family physician at Kaiser Permanente in Fontana, California, and a clinical professor at the University of California Riverside School of Medicine.

Dr Lee is a practicing rheumatologist in Fontana, California

This podcast is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

This podcast is part of the Think Back: Insights Into Axial Spondyloarthritis curriculum.

Episode 3: Referral Tools

Thu, 18 Aug 2022 13:41:16 +0000

Join Dr Abhijeet Danve and Dr Neal Skolnik as they describe how to recognize axSpA among patients with chronic back pain and which patients to refer to rheumatology

Dr Danve is an academic rheumatologist at the Yale School of Medicine in New Haven, Connecticut

Dr Skolnik is an academic family physician at Abington Jefferson Health in Abington, Pennsylvania

This podcast is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

This podcast is part of the Think Back: Insights Into Axial Spondyloarthritis curriculum.

Episode 1: Peripheral Symptoms

Thu, 18 Aug 2022 13:41:09 +0000

Join Dr Reeti Joshi and Dr Ethan Craig as they discuss the peripheral symptoms that can help health care practitioners better diagnose axSpA

Dr Joshi is a rheumatology specialist in Beaumont, Texas

Dr Craig is a rheumatologist at the University of Pennsylvania

This podcast is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

This podcast is part of the Think Back: Insights Into Axial Spondyloarthritis curriculum.

Episode 2: When Pain Hides Inflammatory Disease

Thu, 18 Aug 2022 13:40:58 +0000

Join Dr Neil Skolnik and Dr Ethan Craig as they discuss the underlying biological processes in axSpA

Dr Skolnik is an academic family physician at Abington Jefferson Health in Abington, Pennsylvania

Dr Craig is a rheumatologist at the University of Pennsylvania

This podcast is sponsored by Novartis Medical Affairs, and the speakers have been compensated for their time.

This podcast is part of the Think Back: Insights Into Axial Spondyloarthritis curriculum.

The Patient Voice: Improving Shared Decision-Making in Patients with SLE

Fri, 06 May 2022 15:06:38 +0000

Dr Saira Sheikh and Dr Vera Oyabure discuss their experiences with shared decision-making in SLE, the benefits of involving patients in the decision-making process, and how shared decision-making can be implemented in clinical practice.

Perhaps it’s Lupus? The Importance of Early Diagnosis and Management of SLE

Fri, 06 May 2022 14:56:16 +0000

Dr Saira Sheikh and Dr Vera Oyabure discuss the challenges associated with diagnosing SLE from a multidisciplinary perspective, and why an earlier diagnosis can improve long-term treatment outcomes.

The Burden of SLE: Prevalence, Disparities, and Impact

Fri, 06 May 2022 14:48:38 +0000

Dr Saira Sheikh and Dr Vera Oyabure discuss racial, socioeconomic, and healthcare access disparities in SLE, and their impact on these patient outcomes from a multidisciplinary perspective.

Mission Impossible? Exploring Difficult to Treat Asthma

Tue, 21 Dec 2021 20:08:00 +0000

This case-based podcast focuses on identification of difficult-to-treat asthma and evidence-based techniques for optimizing management.

ACT Now: Determining if Your Patient’s Asthma is Under Control

Tue, 21 Dec 2021 20:07:00 +0000

This podcast discusses the importance of asthma control, including how it is defined, risk factors for poor asthma control and techniques for the assessment of asthma control.

How Real World Evidence Complements Clinical Trials

Tue, 21 Dec 2021 20:06:00 +0000

This podcast explores real world evidence by defining what it is, where it comes from, and its value and application to clinical practice.

Highlights from the American Thoracic Society (ATS) Guidelines 2020

Mon, 20 Dec 2021 15:36:00 +0000

Guests: Gerard J Criner, MD, FACP, FACCP & Jill Ohar, MD, FCCP

For more information, please visit https://www.pri-med.com/podcast/clinical-practice-recommendations-ats

Identifying Patients for De-escalation or Withdrawal of Inhaled Corticosteroids (ICS) in COPD

Mon, 20 Dec 2021 15:36:00 +0000

Guests: MeiLan Han, MD, MS & Barbara P Yawn, MD, MSc, FAAFP

For more information, please visit https://www.pri-med.com/podcast/clinical-practice-recommendations-ics

The Global Initiative For Chronic Obstructive Lung Disease (GOLD) 2021 Report – Takeaways for Healthcare Practitioners

Mon, 20 Dec 2021 15:35:00 +0000

Guests: MeiLan Han, MD, MS & Barbara P Yawn, MD, MSc, FAAFP

For more information, please visit https://www.pri-med.com/podcast/clinical-practice-recommendations-copd-gold

When is LDL-C low enough?

Mon, 20 Dec 2021 15:31:00 +0000

Overview: This podcast discusses the management of low-density lipoprotein cholesterol (LDL-C) and addresses the concept of when LDL-C levels are “low enough” to reduce the risk for atherosclerotic cardiovascular disease.

Guest: Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Shared decision-making in lipid management

Mon, 20 Dec 2021 15:31:00 +0000

Overview: This podcast discusses when patients who are at high risk of cardiovascular disease should be comanaged by primary care providers and lipidologists.

Guest: Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE

Identifying high-risk patients with ASCVD and reducing the burden of elevated LDL-C

Mon, 20 Dec 2021 15:30:00 +0000

Overview: This podcast discusses the identification and management of patients with atherosclerotic cardiovascular disease (ASCVD) and highlights opportunities to reduce the overall burden of elevated low-density lipoprotein cholesterol (LDL-C).

Guest: Norman E. Lepor, MD, FACC, FAHA, FSCAI

Telemedicine and the virtual care of heart disease

Mon, 20 Dec 2021 15:30:00 +0000

Overview: This podcast discusses the evolving role of telemedicine in the virtual care of cardiovascular disease. Best practices for telemedicine and conducting virtual visits in the cardiology sub-specialty are described.

Guest: Ami Bhatt, MD

Effects of long-term exposure to persistently elevated LDL-C

Mon, 20 Dec 2021 15:29:00 +0000

Overview:

This podcast discusses the effects of long-term exposure to persistently elevated low-density lipoprotein cholesterol (LDL-C) on risk for atherosclerotic cardiovascular disease. Four health care providers offer their perspectives from the fields of family medicine, internal medicine, cardiology, and endocrinology.

Guest:

Guy Mintz, MD, FACP, FACC, FASPC, FNLA & James Underberg, MD, PLCC

Living in a World with COVID-19: From Reaction to Action

Thu, 21 Oct 2021 19:55:00 +0000

Overview: The podcast focuses on the scientific understanding of SARS-CoV-2, in addition to the clinical management of patients with COVID-19 or long term sequalae. We bring together healthcare professionals from UK, Canada and Latin America to discuss COVID-19, variants, and how they are managing patients with COVID-19.

Guest: Dr Alexander Liakos

Pandemic in Practice: Impact of Viral Variance, Hyperinflammation and Vaccinations on COVID-19 Outcomes

Thu, 21 Oct 2021 18:17:00 +0000

Overview: This medical podcast will educate attendees on the drivers of COVID-19 in the community, and the factors that contribute to disease progression in the hospital.

Dr. Deepa Gotur will discuss the role of GM-CSF in hyperinflammation in the severe COVID-19 patient.

Guest: Deepa Gotur, MD & Patrick A. Taylor, MD

COVID-19: What Do We Know Now?

Thu, 21 Oct 2021 18:05:00 +0000

Overview: This video will provide attendees an update on COVID-19. Dr. Taylor will discuss current COVID-19 activity globally; review increased transmission as a consequence of variant strains, including the delta variant; and touch briefly on vaccinations and monoclonal antibodies.

Guest: Patrick A. Taylor, MD

Close to the Heart: Assessing Cardiovascular Risk Factors in Our Patients with Type 2 Diabetes

Thu, 22 Jul 2021 16:13:00 +0000

Overview:

Listen as Dr. Eden Miller and Dr. James O’Keefe discuss how diabetes can affect cardiovascular health. These key experts will also review key cardiovascular outcomes trials and their impact on treatment guidance for patients with type 2 diabetes.

Guest: Eden M. Miller, DO & James H. O’Keefe, MD

Close to the Heart: The Impact of Cardiovascular Disease on Patients with Type 2 Diabetes

Thu, 22 Jul 2021 16:11:00 +0000

Close to the Heart: The Impact of Cardiovascular Disease on Patients with Type 2 Diabetes

Close to the Heart: The Increasing Prevalence of Type 2 Diabetes and Associated Comorbidities

Thu, 22 Jul 2021 16:09:00 +0000

Overview:

Guest: Eden M. Miller, DO & James H. O’Keefe, MD

Pulmonary Embolism Trials: Part 3 - Extended VTE Treatment and the 2019 ESC Guidelines

Wed, 30 Jun 2021 16:00:00 +0000

Hear Experts Discuss Extended VTE Treatment with a DOAC versus Aspirin and the 2019 ESC Guidelines on Extension of Treatment after an Initial VTE

Chapter 1 | Classifying Heart Failure

Mon, 28 Jun 2021 14:58:00 +0000

Guests: James O'Keefe, MD & Melissa Magwire, RN, MSN, CDE

For more information, please visit: https://www.pri-med.com/online-education/curriculum/continuum-heart-failure-2021

Chapter 2 | The Interconnected Nature of the Cardio-Renal-Metabolic (CRM) System

Mon, 28 Jun 2021 14:58:00 +0000

Guests: James O'Keefe, MD & Melissa Magwire, RN, MSN, CDE

For more information, please visit: https://www.pri-med.com/online-education/curriculum/continuum-heart-failure-2021

Chapter 3 | Heart Failure and Type 2 Diabetes: Assessment of Patient Care

Mon, 28 Jun 2021 14:58:00 +0000

Guests: James O'Keefe, MD & Melissa Magwire, RN, MSN, CDE

For more information, please visit: https://www.pri-med.com/online-education/curriculum/continuum-heart-failure-2021

Managing ILD Patients During the COVID Pandemic

Mon, 31 May 2021 16:00:00 +0000

Guest: Cori Fratelli, RN

For more information, please visit https://www.pri-med.com/online-education/Curriculum/bi-ofev

Improving the Management of Patients with IPF Through Disease, Symptom, and Support-Centered Management

Mon, 31 May 2021 16:00:00 +0000

Guest: Erica Herzog, MD, PhD & Amy Olson, MD, MSPH

For more information, please visit https://www.pri-med.com/online-education/Curriculum/bi-ofev

How to Recognize the Potential Signs of IPF and Understand When Patients Should be Referred to an ILD Center

Mon, 31 May 2021 16:00:00 +0000

Guest: Erica Herzog, MD, PhD & Marilyn Glassberg, MD

For more information, please visit https://www.pri-med.com/online-education/Curriculum/bi-ofev

Insomnia Insights Episode 1: Finding an Appropriate Treatment for Anne

Wed, 10 Mar 2021 05:00:00 +0000

Guest: Damon Raskin, MD & Seth L. Ivins, MD

For more information, please visit https://www.pri-med.com/online-education/Curriculum/insomnia-insights

Early Detection of Pancreatic Cancer: Pancreatic Cysts & Diabetes

Wed, 11 Nov 2020 18:07:00 +0000

Guest: James Farrell, MBChB & Jeffrey Gorodetsky, MD

For more information, please visit https://www.pri-med.com/online-education/Curriculum/early-detection-of-pancreatic-cancer

Early Detection of Pancreatic Cancer: Genetics & Family History

Wed, 11 Nov 2020 18:07:00 +0000

Guest: James Farrell, MBChB & Jeffrey Gorodetsky, MD

For more information, please visit https://www.pri-med.com/online-education/Curriculum/early-detection-of-pancreatic-cancer

When to be Suspicious of Pancreatic Cancer

Wed, 11 Nov 2020 18:07:00 +0000

Guest: James Farrell, MBChB & Jeffrey Gorodetsky, MD

For more information, please visit https://www.pri-med.com/online-education/Curriculum/early-detection-of-pancreatic-cancer

Uncontrolled Asthma: Practical Considerations for Primary Care

Fri, 25 Sep 2020 04:00:00 +0000

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

Uncontrolled Asthma: Putting Guidelines Into Practice

Fri, 25 Sep 2020 04:00:00 +0000

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

What You Need to Know About Unmet Needs in Asthma

Fri, 25 Sep 2020 04:00:00 +0000

A non-promotional, non-CME educational program brought to you by CHEST in collaboration with GlaxoSmithKline.

The Interplay Between Optimizing Heart Failure Management and Delivering Quality Care

Fri, 04 Sep 2020 17:48:00 +0000

Overview: The clinical course of heart failure is punctuated by multiple episodes of hospitalization,1-3 leading to poor outcomes and high and escalating costs.4,5 This highlights the need to reimagine how heart failure care is delivered. In this episode, featuring Dr Nihar Desai of the Yale School of Medicine, we will explore the interplay between implementing quality improvement initiatives, specifically value-based care models, and optimizing heart failure care.

Faculty: Nihar R. Desai, MD, MPH

Heart Failure Hospitalization: Moving Beyond Symptomatic Management to Optimized Care

Fri, 04 Sep 2020 17:48:00 +0000

Overview: Although heart failure contributes to millions of hospitalizations in the United States each year that significantly impact patient prognosis, treatment is often focused on managing symptoms rather than on optimizing therapy.1,2 In this episode, featuring cardiologist Dr Javed Butler of the University of Mississippi, we will discuss best practices for navigating a heart failure hospitalization, including assessment of the patient’s clinical trajectory and optimization of guideline-directed medical therapy.

Faculty: Javed Butler, MD, MPH, MBA

The Clinical Progression of Heart Failure: Can You Recognize the Signs of Worsening Disease?

Tue, 30 Jun 2020 16:00:00 +0000

Overview: The clinical course of heart failure is progressive and often involves periods of disease worsening that can be challenging to identify for both patients and their health care providers.1-4 In this episode, featuring cardiologist Dr Lee Goldberg of the University of Pennsylvania, we will discuss key aspects of the clinical assessment of heart failure worsening and progression in the outpatient setting and emphasize the importance of optimizing guideline-directed medical therapy in patients with worsening heart failure as well as in those with stable disease.

Faculty: John J. Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA

Heart Failure With Preserved Ejection Fraction: Common, Serious, and Treatable

Tue, 30 Jun 2020 16:00:00 +0000

Overview: Although heart failure with preserved ejection fraction (HFpEF) is common and increasing in prevalence, persistent misconceptions, including a perceived lack of therapeutic options, limit its effective management.1,2 In this episode, featuring cardiologist Dr. John Ryan of the University of Utah, we will counteract these misconceptions through exploration of various HFpEF patient profiles, covering key aspects of HFpEF diagnosis and optimal management in inpatient and outpatient settings.

Faculty: John J. Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA

COPD On Air: Individualizing Treatment

Thu, 11 Jun 2020 03:51:00 +0000

Overview: Host Barry Price is joined by primary care physician Dr. Larry Neuman of Morrison Heights Clinic and nurse practitioner Wendi Haller of [affiliation] to discuss the importance of personalizing chronic obstructive pulmonary disease (COPD) treatment to individual patient needs.

This podcast is intended for U.S. healthcare professionals only and is sponsored by Sunovion Pharmaceuticals, Inc., and includes promotional segments about LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution.

COPD On Air: Identifying gaps in COPD Care

Thu, 11 Jun 2020 03:51:00 +0000

Overview: Host Barry Price is joined by primary care physician Dr. Larry Neuman of Morrison Heights Clinic and Dr. Keith Robinson of Transformative Health Solutions to discuss how treating COPD is not a one size-fits-all approach and how to identify those patients who may be falling through the cracks of traditional treatment methods.

COPD On Air: Let GOLD Be Your Guide

Thu, 11 Jun 2020 03:51:00 +0000

Overview: Host Barry Price is joined by primary care physician Dr. Larry Neuman of Morrison Heights Clinic and Dr. Keith Robinson of Transformative Health Solutions to provide a summary of the 2020 GOLD report and how it translates into their COPD practice.

This podcast is intended for U.S. healthcare professionals only and is sponsored by Sunovion Pharmaceuticals, Inc. and includes promotional segments about LONHALA® MAGNAIR® (glycopyrrolate) Inhalation Solution.

Pri-Med News Episode #18

Thu, 20 Feb 2020 18:09:00 +0000

Topics covered in this episode include:

Out-of-pocket Spending for Maternity Care - 0:30
Physician Ratings Usage in Older Adults - 2:37
Breast Density and Screening Education - 4:46

Pri-Med News Episode #17

Thu, 20 Feb 2020 18:06:00 +0000

Topics covered in this episode include:

HPV Vaccine Rates in Young Adults - 0:30
Opioid Addiction Treatment for Youths - 2:14
Genital Powder Use and Ovarian Cancer - 4:19

Pri-Med News Episode #16

Thu, 20 Feb 2020 18:03:00 +0000

Topics covered in this episode include:

Early Treatment of Concussions - 0:30
Decision aids in Hip and Knee Arthroplasty - 2:20
Testosterone Therapy in Adult Men - 4:44

Pri-Med News Episode #15

Thu, 20 Feb 2020 18:01:00 +0000

Topics covered in this episode include:

Fulminant Myocarditis Management - 0:30
HIV-positive patients and Smallpox Vaccines - 2:33
Active Lifestyle Slowing Dementia- 4:34

Pri-Med News Episode #14

Thu, 20 Feb 2020 17:58:00 +0000

Topics covered in this episode include:

Minimum Wage’s link to Suicide Rates - 0:30
Open Water Regulations and Drowning Death Rates - 2:35
Cancer Mortality Rate Update - 4:45

Pri-Med News Episode #13

Thu, 20 Feb 2020 17:56:00 +0000

Topics covered in this episode include:

Antipsychotic initiation and alzheimers disease - 0:30
Health Administrative Spending Gaps - 2:25
Rise of Electronic Scooter Injuries - 4:18

Pri-Med News Episode #12

Fri, 10 Jan 2020 16:02:00 +0000

Topics covered in this episode include:

Neighborhood Walkability and Cardiovascular Risk - 0:30
Nurse Awareness of Choosing Wisely Campaign - 2:30
Adverse Childhood Experiences’ Impact on Adult Health - 4:55

Pri-Med News Episode #11

Fri, 10 Jan 2020 15:59:00 +0000

Topics covered in this episode include:

RHigh Birth Numbers and Cardiovascular Health - 0:30
Kratom linked to Liver Injury - 2:31
Death rates in Nonmetropolitan Counties - 4:56

Pri-Med News Episode #10

Fri, 10 Jan 2020 15:57:00 +0000

Topics covered in this episode include:

Alzheimer Patients initiating antipsychotic medication - 0:30
Testosterone and Venous Thromboembolism - 3:10
Cardio Risk Factors and Cancer Risk - 5:50

Pri-Med News Episode #9

Fri, 10 Jan 2020 15:54:00 +0000

Topics covered in this episode include:

Smartwatch App and Atrial Fibrillation - 0:30
Lung Cancer Treatment Variations by State - 2:36
Congenital Heart Disease Surgery and Kidney Disease - 4:29

Pri-Med News Episode #8

Fri, 10 Jan 2020 15:50:00 +0000

Topics covered in this episode include:

Illiteracy’s Ties to Dementia - 0:30
Insomnia and CVD Risk - 2:30
Tobacco Cessation for Cancer Patients - 5:05

Pri-Med News Episode #7

Fri, 10 Jan 2020 15:47:00 +0000

Topics covered in this episode include:

Diabetes and Eye Exams - 0:30
Emergency Department Visits for Sports Injuries - 2:29
Vaping-Related Lung Injury - 4:42

Healthcare M&A Is Not for the Faint of Heart

Tue, 24 Dec 2019 13:28:00 +0000

Overview:

90% of physician practice merger and acquisition transactions fail to reach their financial goals (for either side). The reasons vary:

Unrealistic expectations of practice value by the physician
Underestimation of cost and financial performance by the purchaser
Integration of EMRs and technology infrastructure
Inadequate operation optimization
Overvaluation of physician accounts receivable
CPT coding issues

Learn from medical M&A experts how to avoid the pitfalls and maximize your profit potential.

Learning Objectives:

The regulatory constraints covering a practice sale and personal services agreement
(PSA)
Maximizing practice or personal value
Implications of a transaction on office leases and staff
Evaluating fair market value

Guests:

David Audibert, CPA/CVA/MBA and Brad Mondschein, J.D.

Pri-Med News Episode #6

Fri, 25 Oct 2019 14:34:00 +0000

Topics covered in this episode include:

Adolescent Vaping - 0:30
Mortality in Male Breast Cancer Patients - 2:19
PrEP Awareness and Race - 4:43

Pri-Med News Episode #5

Fri, 25 Oct 2019 14:30:00 +0000

Topics covered in this episode include:

Opioid Use After Discharge - 0:30
Obesity Rates in the US - 2:39
HIV's correlation to Atrial Fibrillation - 5:07

Pri-Med News Episode #4

Fri, 25 Oct 2019 14:28:00 +0000

Topics covered in this episode include:

Prevalence of Short Sleep Duration - 0:30
Increase of Suicide Rates among US Youths - 2:19
Bicycle Helmet Underutilization - 4:15

Pri-Med News Episode #3

Fri, 25 Oct 2019 14:26:00 +0000

Topics covered in this episode include:

Tablets and MS Cognitive Assessment - 0:30
Postpartum BP Checks in Women with Hypertension - 2:15
Emergency Department Closures - 4:19

Pri-Med News Episode #2

Fri, 25 Oct 2019 14:24:00 +0000

Topics covered in this episode include:

Acetaminophen in Pregnancy - 0:30
Aspirin for Primary Prevention - 2:37
Caring for Kidney Disease - 4:43

Pri-Med News Episode #1

Fri, 25 Oct 2019 14:20:00 +0000

Topics covered in this episode include:

Professional Coaching and Emotional Exhaustion - 0:30
Electric Fans - 2:37
BP and Waist Measurement in ASCVD/T2DM Prevention - 4:22